Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 133

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 133
---
4 (incorporated by reference to Exhibit 4.15 to the Company’s Annual Report on Form 20-F, filed with the SEC on April 11, 2025).                                                                         |
| 10.16  | Securities Purchase Agreement, dated January 15, 2025, by and between C/M Capital Master Fund, LP, and Biodexa Pharmaceuticals PLC (incorporated by reference to Exhibit 10.1 to the Company’s Report on Form 6-K, filed with the SEC on January 17, 2025).                                 |
| 10.17  | Registration Rights Agreement, dated January 15, 2025, by and between C/M Capital Master Fund, LP, and Biodexa Pharmaceuticals PLC (incorporated by reference to Exhibit 10.2 to the Company’s Report on Form 6-K, filed with the SEC on January 17, 2025).                                 |
| 19.1   | Insider Trading Policy (incorporated by reference to Exhibit 11.1 of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 11, 2025).                                                                                                  |
| 21.1   | Subsidiaries of Biodexa Pharmaceuticals PLC (incorporated by reference to Exhibit 8.1 of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 11, 2025).                                                                              |
| 23.1*  | Consent of PKF Littlejohn LLP, independent registered public accounting firm.                                                                                                                                                                                                               |
| 23.2*  | Consent of Forvis Mazars LLP, independent registered public accounting firm.                                                                                                                                                                                                                |
| 23.3   | Consent of Brown Rudnick (included in Exhibit 5.1).                                                                                                                                                                                                                                         |
| 24.1   | Powers of Attorney (included on signature page).                                                                                                                                                                                                                                            |
| 97.1   | Clawback Policy (incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on April 19, 2024).                                                                                                         |

__

* Filed herewith.

| 

# | Management contract or compensatory plan or arrangement. |
| † | Certain portions of this exhibit (indicated by asterisks